News

Novo Nordisk has reported that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight, after two years of treatment.  

Amgen has reported the results of a new study comparing Nplate (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura

The findings of two 52-week studies showed that the investigational ultra rapid acting insulin Afresa Inhalation Powder, combined with basal insulin, is comparable to standard of care therapies

VIVUS has reported the glycemic findings from Equate, a phase-III trial evaluating Qnexain non-diabetic, obese patients. After 28 weeks of treatment, blood sugar levels, as measured by hemoglobin

Sanofi-Aventis has come up with the results of a new study – Effects of 1, 2, or 3 prandial injections of insulin glulisine on glycemic control in type

Amylin has announced that the use of mealtime Symlin (pramlintide acetate) injection has improved glucose control, treatment satisfaction and quality of life for patients with type 2 diabetes.

XOMA has announced the new results of Xoma 052, as an entirely new anti-inflammatory approach for the treatment of type 2 diabetes. XOMA 052 is a master signaling

Eli Lilly has announced positive phase II study results of LY2189265, an investigational glucagon-like peptide 1 (GLP-1) analog. It is to be administered subcutaneously once a week for

Somaxon, a specialty pharmaceutical company has announced that it has resubmitted New Drug Application (NDA) to FDA for Silenor (doxepin) for the treatment of insomnia. The resubmission includes